Anebulo Pharmaceuticals logo

Anebulo PharmaceuticalsNASDAQ: ANEB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 May 2021

Next earnings report:

13 February 2025

Last dividends:

N/A

Next dividends:

N/A
$39.42 M
-78%vs. 3y high
32%vs. sector
-vs. 3y high
-vs. sector
-23%vs. 3y high
97%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 19 Nov 2024 21:54:05 GMT
$1.52$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ANEB Latest News

Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?
Zacks Investment Research19 October 2023 Sentiment: NEUTRAL

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year.

Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001
Zacks Investment Research22 August 2023 Sentiment: POSITIVE

Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication.

Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year?
Zacks Investment Research12 June 2023 Sentiment: POSITIVE

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.

Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year?
Zacks Investment Research24 May 2023 Sentiment: POSITIVE

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.

What type of business is Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.

What sector is Anebulo Pharmaceuticals in?

Anebulo Pharmaceuticals is in the Healthcare sector

What industry is Anebulo Pharmaceuticals in?

Anebulo Pharmaceuticals is in the Biotechnology industry

What country is Anebulo Pharmaceuticals from?

Anebulo Pharmaceuticals is headquartered in United States

When did Anebulo Pharmaceuticals go public?

Anebulo Pharmaceuticals initial public offering (IPO) was on 07 May 2021

What is Anebulo Pharmaceuticals website?

https://www.anebulo.com

Is Anebulo Pharmaceuticals in the S&P 500?

No, Anebulo Pharmaceuticals is not included in the S&P 500 index

Is Anebulo Pharmaceuticals in the NASDAQ 100?

No, Anebulo Pharmaceuticals is not included in the NASDAQ 100 index

Is Anebulo Pharmaceuticals in the Dow Jones?

No, Anebulo Pharmaceuticals is not included in the Dow Jones index

When was Anebulo Pharmaceuticals the previous earnings report?

No data

When does Anebulo Pharmaceuticals earnings report?

The next expected earnings date for Anebulo Pharmaceuticals is 13 February 2025